Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mineralys Therapeutics (Nasdaq: MLYS) will report its financial results for the second quarter ended June 30, 2026, after market close on Tuesday, August 11, 2026. The company will host a conference call and live webcast at 4:30 p.m. ET for investors and analysts.
Details
News Market Reaction – MLYS
On Aug 4, the day this news came out, MLYS closed 2.79% above the previous close.
Data tracked by StockTitan Argus for the Aug 4 session.
Key Figures
- Reporting period
- Second quarter 2026
- Quarter ended June 30, 2026
- Results announcement date
- August 11, 2026
- After financial markets close
- Conference call time
- 4:30 p.m. ET
- August 11, 2026
Previous Conferences,earnings date Reports
-
Scheduled first-quarter results and conference call after market close on May 6
-
Scheduled fourth-quarter and full-year results with a 4:30 p.m. ET call
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ckd medical
osa medical
aldosterone medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026.
| Tuesday, August 11th @ 4:30 p.m. ET | |
| Domestic: | 1-877-704-4453 |
| International: | 1-201-389-0920 |
| Conference ID: | 13760792 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investors section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.